Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 3/20 | 0.36 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2643813 | 0.93 | LMNA (0.50) | LMNAKDM4EALDH1A1IDO1NOS1 | |
| SCHEMBL9797756 | 0.89 | NOS1 (0.43) | LMNAKDM4EALDH1A1IDO1NOS1 | |
| SCHEMBL34472783 | 0.85 | LMNA (0.58) | LMNAKDM4EALDH1A1IDO1NOS1 | |
| SCHEMBL11836648 | 0.85 | LMNA (0.58) | LMNAKDM4EALDH1A1IDO1NOS1 | |
| SCHEMBL31211054 | 0.76 | LMNA (0.50) | LMNAKDM4EALDH1A1IDO1 | |
| Ligustrazine SCHEMBL27509607 | 0.76 | LMNA (0.41) | LMNAKDM4EALDH1A1NOS1NOS3 | |
| Ligustrazine SCHEMBL77624 | 0.76 | LMNA (0.41) | LMNAKDM4EALDH1A1NOS1NOS3 | |
| SCHEMBL18623479 | 0.73 | LMNA (0.42) | LMNAKDM4EALDH1A1IDO1NOS1 | |
| SCHEMBL10919972 | 0.72 | CCNA2 (0.36) | LMNAKDM4E | |
| SCHEMBL6038800 | 0.71 | LMNA (0.52) | LMNAKDM4EALDH1A1IDO1NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102260218-B | Synthesis method of aminopyrazine spice | BEIJING INST TECHNOLOGY | 2013-05-08 | — | — | CN | claimed |
| CN-102260218-A | Synthesis method of aminopyrazine spice | — | 2011-11-30 | — | — | CN | claimed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | claimed |
| WO-2024182778-A1 | COMPOUNDS AND METHODS FOR MODULATING SPLICING | REMIX THERAPEUTICS INC. (US) | 2024-09-06 | — | — | WO | disclosed |
| EP-3578176-A1 | NON-PLATINUM-BASED ANTI-CANCER COMPOUNDS FOR USE IN TARGETED CHEMOTHERAPY | Lu, Qing-Bin (CA) | 2019-12-11 | — | — | EP | disclosed |
| EP-2935215-B1 | RADIOSENSITIZER COMPOUNDS FOR USE IN COMBINATION WITH RADIATION | LU QING BIN (CA) | 2019-11-13 | — | — | EP | disclosed |
| CN-104364249-B | Triazol compound as PDE10 inhibitor | 霍夫曼-拉罗奇有限公司 | 2018-04-17 | — | — | CN | disclosed |
| EP-2855455-B1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2017-11-08 | — | — | EP | disclosed |
| US-9394311-B2 | Triazolo compounds as PDE10 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2016-07-19 | — | — | US | disclosed |
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2015-05-28 | — | — | US | disclosed |
| EP-2855455-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-5378691-A | Amino acid derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1995-01-03 | — | — | US | disclosed |
| EP-0418696-A2 | Derivatives of aminoacids | MERCK PATENT GmbH (DE) | 1991-03-27 | — | — | EP | disclosed |
| US-4895702-A | FORMING FILMS ON METAL TOOLS AND EQUIPMENT USED IN DRILLING AND SERVICING OF GAS AND OIL WELLS; HIGH AND LOW TEMPERATURE AND PRESSURE RESISTANT | THE DOW CHEMICAL COMPANY (US) | 1990-01-23 | — | — | US | disclosed |
| EP-0342325-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-11-23 | — | — | EP | disclosed |
| CN-1037155-A | Amino acid derivative | MERCK PATENT GMBH (DE) | 1989-11-15 | — | — | CN | disclosed |
| EP-0337334-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-10-18 | — | — | EP | disclosed |
| EP-0330925-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1989-09-06 | — | — | EP | disclosed |
| EP-0264795-A2 | Amino acid derivatives | MERCK PATENT GmbH (DE) | 1988-04-27 | — | — | EP | disclosed |
| EP-0249096-A2 | Renin-inhibiting amino acid derivatives | MERCK PATENT GmbH (DE) | 1987-12-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148332-A1 | TRIAZOLO COMPOUNDS AS PDE10 INHIBITORS | PDE3A, PDE3B, PDE5A | LMNA 3072/4885KDM4E 1649/4885ALDH1A1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.